AU2020319899B2 - Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics - Google Patents

Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Info

Publication number
AU2020319899B2
AU2020319899B2 AU2020319899A AU2020319899A AU2020319899B2 AU 2020319899 B2 AU2020319899 B2 AU 2020319899B2 AU 2020319899 A AU2020319899 A AU 2020319899A AU 2020319899 A AU2020319899 A AU 2020319899A AU 2020319899 B2 AU2020319899 B2 AU 2020319899B2
Authority
AU
Australia
Prior art keywords
antibody
galectin
subject
dose
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020319899A
Other languages
English (en)
Other versions
AU2020319899A1 (en
Inventor
Joseph BOLEN
Linxiao CHEN
Eric Elenko
Aleksandra Filipovic
Akiko Koide
Shohei Koide
George Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Puretech LYT Inc
Original Assignee
New York University NYU
Puretech LYT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/031181 external-priority patent/WO2020223702A1/en
Application filed by New York University NYU, Puretech LYT Inc filed Critical New York University NYU
Publication of AU2020319899A1 publication Critical patent/AU2020319899A1/en
Application granted granted Critical
Publication of AU2020319899B2 publication Critical patent/AU2020319899B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020319899A 2019-08-01 2020-08-03 Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics Active AU2020319899B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962881894P 2019-08-01 2019-08-01
US62/881,894 2019-08-01
PCT/US2020/031181 WO2020223702A1 (en) 2019-05-01 2020-05-01 Anti-galectin-9 antibodies and uses thereof
AUPCT/US2020/031181 2020-05-01
PCT/US2020/044777 WO2021022256A1 (en) 2019-08-01 2020-08-03 Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Publications (2)

Publication Number Publication Date
AU2020319899A1 AU2020319899A1 (en) 2022-02-24
AU2020319899B2 true AU2020319899B2 (en) 2026-04-09

Family

ID=74229293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020319899A Active AU2020319899B2 (en) 2019-08-01 2020-08-03 Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Country Status (7)

Country Link
US (1) US20220332832A1 (https=)
EP (1) EP4007640A4 (https=)
JP (1) JP7703513B2 (https=)
CN (1) CN114502241B (https=)
AU (1) AU2020319899B2 (https=)
CA (1) CA3149324A1 (https=)
WO (1) WO2021022256A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223704A1 (en) * 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof
JP2024519450A (ja) * 2021-04-30 2024-05-14 ピュアテック・エル・ワイ・ティ・インコーポレイテッド 抗ガレクチン－９抗体及びその治療的使用
WO2022232653A1 (en) * 2021-04-30 2022-11-03 Puretech Lyt, Inc. Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
CN113624965B (zh) * 2021-08-05 2024-02-09 中国人民解放军军事科学院军事医学研究院 N蛋白特异性IgG4在甄别新型冠状病毒感染者和疫苗接种者中的应用
CA3233331A1 (en) * 2021-10-01 2023-04-06 Puretech Lyt, Inc. Anti-galectin-9 antibodies and therapeutic uses thereof
CN119286974A (zh) * 2024-12-12 2025-01-10 南方医科大学南方医院 一种晚期结直肠癌靶向治疗预测模型的构建系统
CN120585880B (zh) * 2025-08-07 2025-12-09 四川大学华西医院 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084553A1 (en) * 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
FR3021970B1 (fr) * 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
WO2016008005A1 (en) * 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Galectin immunotherapy
CN110248674B (zh) * 2016-09-07 2021-10-26 萨辛生命科学有限公司 针对vegf的合成抗体及其用途
SG11202001606XA (en) * 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084553A1 (en) * 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
JP7703513B2 (ja) 2025-07-07
CA3149324A1 (en) 2021-02-04
WO2021022256A1 (en) 2021-02-04
CN114502241B (zh) 2026-04-03
US20220332832A1 (en) 2022-10-20
EP4007640A4 (en) 2023-10-04
EP4007640A1 (en) 2022-06-08
JP2022543780A (ja) 2022-10-14
AU2020319899A1 (en) 2022-02-24
CN114502241A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
AU2020319899B2 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP7581238B2 (ja) 抗ガレクチン９抗体およびその使用
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
EP4232089A1 (en) Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
US20240109968A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20240182583A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20240190970A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
HK40074716A (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CN117580589A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
WO2023056461A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
HK40108543A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
HK40069657A (en) Anti-galectin-9 antibodies and uses thereof
HK40069657B (zh) 抗半乳糖凝集素-9 抗体及其用途